PVLA (PVLA) Earnings Call Analysis

8/25

Growth 2 Margin 1 Expansion 3 Platform 0 Financial 2

latest quarter score

Earnings Reports

8
Povella Therapeutics (PVLA) Q2 2026: $230M Raise Fuels 40-Rep Launch Surge for First-in-Disease Pipeline
August 04, 2026
12
PVLA Q1 2026: $230M Financing Extends Runway, Accelerates Rare Disease Launch Ambitions
May 07, 2026
10
Povella Therapeutics (PVLA) Q4 2025: $230M Raise Extends Runway Through First-Line Launch
March 31, 2026
10
Palvella (PVLA) Q3 2025: Pipeline Expands to Four Rare Disease Programs as Platform Strategy Accelerates
November 11, 2025
10
Palvela (PVLA) Q2 2025: SELVA Phase 3 Enrollment Exceeds Target by 25%, Setting Up Four Major Catalysts
August 15, 2025
8
Palvella Therapeutics (PVLA) Q1 2025: Exceeds Phase 3 Enrollment Target, Advancing Toward NDA Submission in 2026
May 15, 2025
8
Palvella Therapeutics (PVLA) Q4 2024: $83.6M Cash Runway Fuels Rare Skin Disease Pipeline Expansion
March 31, 2025

Browse all companies